Patents Assigned to GW Pharma Limited
  • Patent number: 9066920
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 30, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Patent number: 9035130
    Abstract: The invention relates to a reference plant which has been selected to: a) not express a medicinally active compound or group of compounds; yet b) express, at least substantially qualitatively, most other non medicinally active compounds present in a therapeutically active comparator plant. The reference plant can be used to generate a reference extract with a reference chemical profile which resembles that of the comparator plant less the active compound or group of compounds and may thus be used as a placebo or to otherwise test the hypothesis that the active compound or compounds are responsible for an extracts perceived medicinal activity.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: May 19, 2015
    Assignee: GW Pharma Limited
    Inventor: Etienne De Meijer
  • Patent number: 9034395
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 19, 2015
    Assignee: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy, David Downs, David W. Pate
  • Patent number: 9029423
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: May 12, 2015
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 9017737
    Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 28, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
  • Publication number: 20150086653
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 26, 2015
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Publication number: 20140378539
    Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 25, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
  • Publication number: 20140377382
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 25, 2014
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20140296351
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 2, 2014
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 8846409
    Abstract: The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: September 30, 2014
    Assignee: GW Pharma Limited
    Inventors: Ian R. Flockhart, Gary William Wheatley, Su Dring, Leslie Archer
  • Publication number: 20140287067
    Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
    Type: Application
    Filed: November 14, 2013
    Publication date: September 25, 2014
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Guillermo Velasco Diez, Manuel Guzman Pastor, Mar Lorente, Sofia Torres, Fatima Rodriguez
  • Publication number: 20140243405
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Application
    Filed: September 14, 2012
    Publication date: August 28, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens
  • Publication number: 20140221469
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.
    Type: Application
    Filed: September 10, 2012
    Publication date: August 7, 2014
    Applicants: Otsuka Pharmaceutical Co., Ltd., GW Pharma Limited
    Inventors: Ruth Alexandra Ross, Daniela Parolaro
  • Patent number: 8790719
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: July 29, 2014
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Patent number: 8771760
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: July 8, 2014
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson
  • Publication number: 20140155456
    Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
    Type: Application
    Filed: January 3, 2012
    Publication date: June 5, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens
  • Publication number: 20140107192
    Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 17, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
  • Patent number: 8673368
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: March 18, 2014
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20140039043
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: February 6, 2014
    Applicant: GW Pharma Limited
    Inventor: GW Pharma Limited
  • Patent number: 8632825
    Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: January 21, 2014
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Guillermo Velasco Diez, Manuel Guzman Pastor, Mar Lorente, Sofia Torres, Fatima Rodriguez